Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Cancer Causes & Control : CCC
|
August 2, 2023
Subsequent primary neoplasms after childhood cancer therapy - design and description of the German nested case-control study STATT-SCAR
Peter Scholz-Kreisel, Cornelia Becker, Melanie Kaiser, et al.
Journal of Cancer Research and Clinical Oncology
|
May 24, 2017
Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)
Hannah Tessenow, Madlen Holzvogt, Bruno Holzvogt, et al.
Journal of Cancer Research and Clinical Oncology
|
August 23, 2017
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)
Juliane Beck, Andreas Schwarzer, Dietrich Gläser, et al.
Journal of Cancer Research and Clinical Oncology
|
November 28, 2012
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
Wolfram Pönisch, Malvina Bourgeois, Barbara Moll, et al.
Journal of Cancer Research and Clinical Oncology
|
September 19, 2013
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure
Wolfram Pönisch, Barbara Moll, Malvina Bourgeois, et al.
Journal of Cancer Research and Clinical Oncology
|
January 12, 2021
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)
Tanja Holzhey, Wolfram Pönisch, Song-Yau Wang, et al.
Journal of Cancer Research and Clinical Oncology
|
August 20, 2022
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study
Song-Yau Wang, Tanja Holzhey, Simone Heyn, et al.
Journal of Cancer Research and Clinical Oncology
|
May 16, 2015
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma
Wolfram Poenisch, Madlen Plötze, Bruno Holzvogt, et al.
Journal of Cancer Research and Clinical Oncology
|
June 20, 2014
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma
Wolfram Pönisch, Bruno Holzvogt, Madlen Plötze, et al.
Health Research Policy and Systems
|
February 27, 2025
The EU project Real4Reg: unlocking real-world data with AI
Jonas Peltner, Cornelia Becker, Julia Wicherski, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Cancer Causes & Control : CCC
|
August 2, 2023
Subsequent primary neoplasms after childhood cancer therapy - design and description of the German nested case-control study STATT-SCAR
Peter Scholz-Kreisel, Cornelia Becker, Melanie Kaiser, et al.
Journal of Cancer Research and Clinical Oncology
|
May 24, 2017
Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)
Hannah Tessenow, Madlen Holzvogt, Bruno Holzvogt, et al.
Journal of Cancer Research and Clinical Oncology
|
August 23, 2017
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)
Juliane Beck, Andreas Schwarzer, Dietrich Gläser, et al.
Journal of Cancer Research and Clinical Oncology
|
November 28, 2012
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
Wolfram Pönisch, Malvina Bourgeois, Barbara Moll, et al.
Journal of Cancer Research and Clinical Oncology
|
September 19, 2013
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure
Wolfram Pönisch, Barbara Moll, Malvina Bourgeois, et al.
Journal of Cancer Research and Clinical Oncology
|
January 12, 2021
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)
Tanja Holzhey, Wolfram Pönisch, Song-Yau Wang, et al.
Journal of Cancer Research and Clinical Oncology
|
August 20, 2022
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study
Song-Yau Wang, Tanja Holzhey, Simone Heyn, et al.
Journal of Cancer Research and Clinical Oncology
|
May 16, 2015
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma
Wolfram Poenisch, Madlen Plötze, Bruno Holzvogt, et al.
Journal of Cancer Research and Clinical Oncology
|
June 20, 2014
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma
Wolfram Pönisch, Bruno Holzvogt, Madlen Plötze, et al.
Health Research Policy and Systems
|
February 27, 2025
The EU project Real4Reg: unlocking real-world data with AI
Jonas Peltner, Cornelia Becker, Julia Wicherski, et al.
Page
of 3